Sentence examples for dose modification factor from inspiring English sources

Moreover the dose modification factor (DMF) for the PtII agents were lower than those for PtIV agents in the three cell lines.

The dose modification factor for tetraplatin after BSO treatment was similar to that observed for melphalan in all three cell lines.

At a level of 40 regenerated crypts, radiosensitization was observed for a 3 h time interval (dose modification factor of 1.3) and was associated with DNA synthesis inhibition, whereas a slight radioprotection was observed for a 48-h time interval (dose modification factor of 0.9) when DNA synthesis has reinitiated.

A relative resistance value was calculated as the dose modification factor (DMF) for 90% cell kill (ratio of dose required to kill 90% cells in the inner-fractions compared with that in the B fraction).

From the LoVo radiation dose response curve, the time to achieve RTV4 for ZD1839 plus 5 Gy was equivalent to that which would be obtained for a single dose of 8 Gy, giving a radiation dose modification factor of 1.6 for the combined therapy.

The radiation dose modification factors (DMFs) were calculated as the ratio of radiation doses producing equivalent surviving fractions following the FTD/IR treatment, or IR alone.

Dose modification factors (DMFs) of between 1.13-1.24 were obtained.

Dose modification factors of between 1.3 and 1.6 were observed using in vivo/in vitro clonogenic assays.

Using an in vivo-in vitro tumour-excision assay, the administration of MISO simultaneously with or 3 h after low doses of BCNU (less than 20 mg/kg) was found to give a dose-modification factor (DMF) of approximately 1.65 relative to BCNU alone.

There was no threshold in nitroimidazole dose required to produce this potentiation, the degree of potentiation increasing with dose, albeit at a diminishing rate, to give maximum dose-modification factors of about 3. The 6 nitroimidazole compounds in order of increasing effectiveness as potentiators of melphalan activity were: METRO, Ro 05-9963, MISO, RSU 1047, Ro 03-8800 and Ro 03-8799.

Neutropaenia, which occurred primarily within the first 30 days of treatment, was generally manageable with prompt dose modification, growth factors, and antibiotics.